Biotech Hiring Strategy: The Drug Development Map

Biotech Hiring Strategy Across the Drug Development Lifecycle – Why Most Biotech Hiring Strategies Are Built to Fail

Bringing a new drug to market is one of the most complex, expensive, and time-sensitive endeavours in any industry. The Tufts Center for the Study of Drug Development estimates the total cost of getting a new medicine to patients at approximately $2.6 billion –  a figure that reflects not just successful programmes, but the weight of every candidate that never made it. With that kind of capital at stake, it is striking how many biotechs still approach hiring reactively, filling roles only once the pressure is already being felt.

The drug development lifecycle (DDL) is not unpredictable. Discovery, preclinical work, regulatory filing, clinical phases, approval, launch, and post-market surveillance each follow a broadly understood sequence and timeline. The science may be uncertain, but the structure is not. And yet the talent strategies of even well-funded biotechs frequently lag behind the operational reality of each stage – a disconnect that quietly compounds delays, increases costs, and puts programmes at risk.

The Structural Problem With Reactive Hiring

In a 2024 industry survey conducted by Thermo Fisher Scientific’s PPD clinical research business, nearly half of all drug developers – 45% – reported extended clinical development timelines, with delays ranging from one month to more than two years. The same survey found that 49% of drug developers identified rising costs as their single greatest challenge. These two pressures are rarely independent. Timeline delays and cost overruns are frequently rooted in the same cause: the right people were not in place at the right time.

This is not a criticism of the people running these organisations. Early-stage biotechs are lean by necessity, and building out large teams before a programme has validated itself is not prudent capital deployment. But there is a significant difference between being deliberately lean and being unintentionally underprepared. The former is strategic; the latter is a risk that compounds over time.

What Each Stage Actually Demands in Talent Terms

Understanding the DDL as a hiring map – rather than just a scientific sequence – changes the way organisations plan.

Discovery and preclinical phases are often the least pressured from a headcount perspective, but they set the foundation. Molecular biologists, computational scientists, medicinal chemists, toxicologists, and GLP quality assurance professionals need to be embedded early, not recruited in parallel with the science they are supposed to be conducting. Hiring for preclinical work typically needs to begin six to twelve months before GLP studies are scheduled to start.

Regulatory filing is a stage that consistently catches organisations off guard. The IND submission to the FDA in the US, or the CTA process across individual EU member states in EMEA, requires regulatory affairs professionals, CMC specialists, and medical writers who are experienced in the specific nuances of each system. These are not generalist roles. In EMEA particularly, the CTA pathway requires country-by-country navigation involving local ethics committees and national competent authorities – a process with meaningful complexity that demands specialists, not generalists learning on the job. Hiring for this stage should ideally begin twelve months before planned submission.

Phases I – III

Phases I through III represent an escalating build in both scientific and operational complexity. Phase III is the most consequential: it is the largest, most expensive trial phase, requires the broadest cross-functional team, and directly generates the data on which approval decisions are made. Organisations that begin hiring for Phase III less than nine to twelve months before programme initiation regularly find themselves scrambling for senior clinical operations professionals, statisticians, supply chain specialists, and regulatory leads in a competitive market.

Commercial preparation is where the US and EMEA landscapes diverge most sharply. In the US, a successful FDA approval unlocks a unified national market. In EMEA, approval via the EMA’s centralised procedure is only the beginning: companies then face 27 distinct HTA, pricing, and reimbursement systems, each with its own timelines, evidence requirements, and stakeholder dynamics. Market access professionals, HEOR specialists, and country-specific medical science liaisons are not roles that can be hired in the six months prior to launch. The runway for commercial talent – particularly in EMEA – is twelve to twenty-four months.

The US and EMEA Hiring Landscape Are Not the Same

One of the more commonly underestimated risks for biotechs scaling transatlantically is the assumption that regulatory and talent markets are broadly similar on both sides of the Atlantic. They are not.

Beyond the well-known differences between FDA and EMA approval pathways, the talent pools themselves differ. EU regulatory affairs professionals with deep CTA expertise across multiple member states are a distinct population from their US counterparts. Commercial talent experienced in navigating AMNOG in Germany, early access programmes in France, or NICE submissions in the UK requires specialised knowledge that is not interchangeable. Hiring timelines also tend to extend as programmes advance in complexity, making early identification of candidates  – well before a role is formally opened  – a practical necessity rather than a luxury.

Treating Funding Events as Hiring Signals

One of the more actionable shifts a leadership team can make is to treat financing milestones not just as operational enablers but as explicit triggers for talent planning. A Series B that funds Phase 2 entry is not simply capital for clinical activity – it is a signal that, within a defined window, an organisation will need scientific and clinical leadership in place and ready to execute. A Series C or equivalent that enables Phase 3 initiation typically marks the point at which an organisation faces its largest and most complex single hiring surge.

Recognising these inflection points in advance – and beginning talent identification before the formal need becomes acute – is the difference between hiring that enables the science and hiring that delays it.

Building a Hiring Strategy That Mirrors the Science

The drug development lifecycle is predictable in its structure, even when outcomes are not. That predictability is an asset that relatively few biotechs exploit systematically in their talent planning. Organisations that treat each DDL stage as a defined hiring horizon – mapping what roles are needed, in which geographies, at what seniority, and how far in advance of each milestone – tend to move faster, experience fewer bottlenecks, and protect more of the capital they have worked hard to raise.

In an environment where, according to PPD’s research, nearly half of all drug developers are already experiencing significant timeline extensions, the cost of reactive hiring is not theoretical. It is measurable, and it compounds across every stage of development.

The science dictates the timeline. The timeline dictates the hiring. Getting the sequencing right is one of the most consequential operational decisions a growing biotech will make.

By Dan Bennett, Client Services Director, Skills Alliance